Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11629
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChua, Horng-Rueyen
dc.contributor.authorBaldwin, Ianen
dc.contributor.authorHo, Lisaen
dc.contributor.authorCollins, Allison Len
dc.contributor.authorAllsep, Helenen
dc.contributor.authorBellomo, Rinaldoen
dc.date.accessioned2015-05-16T01:14:44Z
dc.date.available2015-05-16T01:14:44Z
dc.date.issued2012-12-12en
dc.identifier.citationBlood Purification 2012; 34(3-4): 306-12en
dc.identifier.govdoc23235269en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11629en
dc.description.abstractTo examine biochemical effects of phosphate-containing replacement fluid (Phoxilium(®)) for continuous venovenous hemofiltration (CVVH).Retrospective comparison of respective serum biochemistry with sequential use of Accusol™ and Phoxilium, each over 48 h of CVVH.We studied 15 critically ill patients. Accusol was switched to Phoxilium after 5 (4-8) days of CVVH. Respective serum biochemistry after 36-42 h of Accusol versus Phoxilium were: phosphate 1.02 (0.82-1.15) versus 1.44 (1.23-1.78) mmol/l, ionized calcium 1.28 (1.22-1.32) versus 1.12 (1.06-1.21) mmol/l, bicarbonate 24 (23-25) versus 20 (19-22) mmol/l, base excess 0 (-2 to 1) versus -4 (-6 to -3) mmol/l (p < 0.001). Cumulative phosphate intakes during respective periods were 69.6 (56.6-76.6) versus 67.2 (46.6-79.0) mmol (p = 0.45). Plasma strong ion differences were narrower with Phoxilium (p < 0.05), with similar strong ion gaps. No additional intravenous phosphate was given during Phoxilium use. Seven patients had serum phosphate >1.44 mmol/l.Phoxilium versus Accusol use during CVVH effectively prevented hypophosphatemia but contributed to mild hyperphosphatemia, and is associated with relative hypocalcemia and metabolic acidosis.en
dc.language.isoenen
dc.subject.otherAPACHEen
dc.subject.otherAcute Kidney Injury.blood.complications.therapyen
dc.subject.otherAgeden
dc.subject.otherElectrolytes.blood.chemistryen
dc.subject.otherFemaleen
dc.subject.otherHemodialysis Solutions.chemistryen
dc.subject.otherHemofiltration.adverse effects.methodsen
dc.subject.otherHumansen
dc.subject.otherHypophosphatemia.etiology.prevention & controlen
dc.subject.otherIntensive Care Unitsen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherPhosphates.blood.chemistryen
dc.subject.otherRetrospective Studiesen
dc.subject.otherTime Factorsen
dc.titleBiochemical effects of phosphate-containing replacement fluid for continuous venovenous hemofiltration.en
dc.typeJournal Articleen
dc.identifier.journaltitleBlood purificationen
dc.identifier.affiliationDepartment of Intensive Care, Austin Health, Heidelberg, Victoria, Australia., Australiaen
dc.identifier.doi10.1159/000345343en
dc.description.pages306-12en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/23235269en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.